Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.6.2841

Association Between MDM2 Promoter SNP309 T/G Polymorphism and Liver Cancer Risk - a Meta-analysis  

Ma, Hong-Bo (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University)
Huang, Tao (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University)
Han, Feng (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University)
Chen, Wei-Yu (Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, the Affiliated Tumor Hospital of Zhengzhou University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.6, 2012 , pp. 2841-2846 More about this Journal
Abstract
Background: Many studies have investigated the association between the MDM2 promoter SNP309 T/G polymorphism and liver cancer risk, but inconsistencies make drawwing definitive conclusions difficult. Methods: We therefore searched main databases for articles relating MDM2 SNP309 T/G polymorphism to risk of liver cancer in humans and estimated summary odds ratio (OR) with 95% confidence intervals (95% CI) to assess the possible association in a meta-analysis. Results: The main analysis revealed no significant heterogeneity, and the pooled ORs of fixed-effects were all significant (for G versus T, OR = 1.59, 95% CI 1.42-1.78; for GG versus TT, OR = 2.45, 95% CI 1.93-3.12; for GT versus TT, OR = 1.70, 95% CI 1.38-2.09; for GG versus GT, OR = 1.49, 95% CI 1.24-1.79; for GG and GT versus TT, OR = 1.95, 95% CI 1.61-2.38; for GG versus TT and GT, OR = 1.73, 95% CI 1.46-2.07). Subgroup analyses by ethnicity and sensitivity analyses both showed associations to remain significant. Conclusion: The present meta-analysis of available data showed a significant association between the MDM2 SNP309 T/G polymorphism and liver cancer risk, the MDM2 SNP309 G allele contributing to increased risk in both Asians and Caucasians in a graded, dose-dependent fashion.
Keywords
Liver cancer; MDM2; polymorphism; risk factor; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Hu Z, Jin G, Wang L, et al (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomark Prev, 16, 2717-23.   DOI
2 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
3 Jung CR, Lim JH, Choi Y, et al (2010). Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest, 120, 4493-506.   DOI
4 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
5 Kimman M, Norman R, Jan S, et al (2012). The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20.   DOI
6 Lauria A, Tutone M, Ippolito M, et al (2010). Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem, 17, 3142-54.   DOI
7 Leu JD, Lin IF, Sun YF, et al (2009). Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol, 15, 5592-7.   DOI
8 Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology. JAMA, 283, 2008.   DOI
9 Muellerleile P, Mullen B (2006). Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health, 96, 515-22.   DOI
10 Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7.   DOI
11 Wang B, Huang G, Wang D, et al (2010). Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol, 53, 508-18.   DOI   ScienceOn
12 Wilkening S, Bermejo JL, Hemminki K (2007). MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 28, 2262-7.   DOI
13 Wang X, Zhang X, Qiu B, et al (2012). MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int, 32, 1172-8.   DOI
14 Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107.   DOI   ScienceOn
15 Wiangnon S, Kamsa-Ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990 - 2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8.   DOI   ScienceOn
16 Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
17 Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6.   DOI   ScienceOn
18 Zhang MF, Zhang ZY, Fu J, et al (2009). Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med, 7, 110.   DOI
19 Zintzaras E, Lau J (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 61, 634-45.   DOI
20 Akkiz H, Sumbul AT, Bayram S, et al (2010). MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol, 34, 448-52.   DOI
21 Chen WQ (2009). Estimation of cancer incidence and mortality in China in 2004-2005. Chin J Cancer, 31, 664-8.
22 Cheok CF, Verma CS, Baselga J, et al (2011). Translating p53 into the clinic. Nat Rev Clin Oncol, 8, 25-37.   DOI
23 Dharel N, Kato N, Muroyama R, et al (2006). MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 12, 4867-71.   DOI
24 Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.   DOI
25 Deisenroth C, Zhang Y (2010). Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene, 29, 4253-60.   DOI
26 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI
27 Economopoulos KP, Sergentanis TN (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat, 120, 211-6.   DOI
28 Di Vuolo V, Buonaguro L, Izzo F, et al (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer, 6, 13.   DOI
29 Ding C, Yu H, Qin H (2012). TP53 Codon 72 Polymorphism with Hepatocellular Carcinoma: a Metaanalysis. J Int Med Res, 40, 446-54.   DOI   ScienceOn
30 Dongiovanni P, Fracanzani AL, Cairo G, et al (2010). Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol, 176, 1006-17.   DOI
31 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI
32 Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI   ScienceOn
33 El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27.   DOI   ScienceOn
34 Embade N, Fernandez-Ramos D, Varela-Rey M, et al (2012). Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 55, 1237-48.   DOI
35 Ezzikouri S, El Feydi AE, Afifi R, et al (2009). MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev, 32, 380-5.   DOI
36 Ezzikouri S, Essaid El Feydi A, Afifi R, et al (2011). Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers, 26, 229-33.
37 Fang F, Yu XJ, Yu L, et al (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol, 28, 981-5.   DOI
38 Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.   DOI
39 Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35.   DOI   ScienceOn